Table 2.
Early prediction of in-hospital mortality was analyzed by Cox regression analysis (derivation and validation cohorts)
| Variables | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|
| HR (95% CI) | P | HR (95% CI) | P | |
| Derivation cohort | ||||
| Sex* | 0.673 (0.336-1.345) | .262 | ||
| Age, y | 1.027 (1.004-1.051) | .019 | 2.991 (1.052-8.500) | .040 |
| Comorbidity (yes/no) | 0.431 (0.153-1.212) | .111 | ||
| Therapy† | 0.467 (0.239-0.914) | .026 | 0.660 (0.239-1.818) | .421 |
| PaO2/FIO2‡ | 0.998 (0.995-1.001) | .267 | ||
| INR‡ | 0.980 (0.926-1.037) | .483 | ||
| Bilirubin‡ | 0.921 (0.731-1.162) | .488 | ||
| CRP‡ | 1.022 (0.993-1.052) | .142 | ||
| Platelets‡ | 0.417 (0.233-0.746) | .003 | 0.805 (0.293-2.216) | .675 |
| D-dimer‡ | 1.667 (0.839 −3.314) | .145 | ||
| vWF | 1.255 (0.078-20.147) | .873 | ||
| IL-6§ | 1.158 (0.464-2.915) | .755 | ||
| Endoglin§ | 1.366 (0.085-2.084) | .825 | ||
| Angiopoietin-2§ | 5.502 (1.558-19.431) | .008 | 6.692 (1.852-24.188) | .004 |
| Tie2§,|| | 2.724 (1.008-7,352) | .048 | ||
| Validation cohort | ||||
| Sex* | 0.653 (0.188-2.270) | .502 | ||
| Age, y | 2.631 (0.983-7.040) | .054 | 2.146 (0.782-5.893) | .138 |
| Comorbidity (yes/no) | 0.553 (0.193-1.581) | .269 | ||
| Therapy† | 0.655 (0.362-1.183) | .160 | ||
| PaO2/FIO2‡ | 0.996 (0.991-1.002) | .216 | ||
| Platelets‡ | 1.292 (0.508-3.283) | .591 | ||
| D-dimer‡ | 0.012 (0.000-17.869) | .236 | ||
| IL-6§ | 1.544 (0.472-5.055) | .473 | ||
| Endoglin§ | 1.059 (0.402-2.784) | .908 | ||
| Angiopoietin-2§ | 4.592 (1.473-14.317) | .009 | 4.447 (1.435-13.777) | .010 |
| Tie2§,|| | 3.223 (1.112-9.341) | .031 | ||
INR, international normalized ratio.
*
Female reference.
†
Hydroxychloroquine + enoxaparin + tocilizumab vs other regimens (reference).
‡
Values above median vs below median.
§
Three-day course.
||
Tie2 was not included in multivariate analysis, being colinear with angiopoietin-2.